Evommune (EVMN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.89
- Estimate
- -$0.67
- Surprise
- -32.8%
- Score today
- 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Evommune (EVMN) reported a wider loss than forecast — adjusted EPS of -$0.89 against the -$0.67 estimate (a 32.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates EVMN Hold at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 3 quarters beat the estimate; this quarter's -32.8% surprise compares with a -24.6% four-quarter average. Next scheduled report: 2026-11-16.
What argues against it
- Market cap $319M below $400M minimum
- Momentum score 3.3/10 — below 4.5 minimum
- Death cross — 50-day MA below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.49
- Price target
- $20.99
- Stop
- $8.00
- Upside to target
- +147.2%
- Reward-to-risk
- 9.8:1
Risk check: RSI 20 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-26 — shown for context, not personalized investment advice.
EVMN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $319.4M
- P/E (fwd)
- -2.6
- 52-week range
- $8.25–$33.20
- Off 52-week high
- 74.4%
- RSI (14)
- 20
- Volume vs avg
- 0.69×
- Score today
- 5.0/10